日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Author Correction: An orally available M(pro)/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo

作者更正:一种口服有效的M(pro)/TMPRSS2双特异性抑制剂在体内具有强大的抗冠状病毒功效

Shuai, Huiping; Qiao, Jingxin; Yoon, Chaemin; Zhang, Guo; Hou, Yuxin; Xia, Xiaoyan; Wang, Lei; Deng, Xinyue; Wang, Yifei; Li, Qingquan; Du, Lianzhao; Liu, Yuanchen; Zhou, Minmin; Wong, Hoi Ting; Hu, Jiaheng; Liu, Huan; Hu, Bingjie; Wang, Dong; Su, Jingyi; Pan, Yuying; Ye, Yongtao; Chen, Yan; Fang, Zhen; Xia, Ziyi; Chai, Yue; Shi, Jialu; Wang, Yang; Zhu, Tianrenzheng; Zhang, Honglei; Yuan, Shuofeng; Zhou, Jie; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung; Xu, Chunfu; Lei, Jian; Yang, Shengyong; Chu, Hin

Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution.

孤儿广谱 RBD 结合抗体对 SARS-CoV-2 进化过程中剩余的三个保守 RBD 表位进行了注释。

Xie Minxiang, Qiu Yinong, Zhao Xiaoyu, Shi Jialu, Liu Yuanchen, Zhang Qingsong, He Jiaying, Li Jiayan, Liu Luotian, Sun Siyuan, Zhu Yuzhen, Mao Qiyu, Long Yiming, Oliveira Thiago Y, Wang Zijun, Zhou Yunjiao, Yan Yan, Xia Anqi, Zai Wenjing, Mayer Christian T, Xie Youhua, Jiang Shibo, Lu Lu, Xia Rong, Wu Fan, Sun Lei, Wang Pengfei, Chu Hin, Wang Qiao

Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.

SARS-CoV-2 JN.1 衍生变体(包括 JN.1.7、KP.2、KP.3 和 KP.3.1.1)的致病性、病毒学特征和免疫逃避。

Shi Jialu, Zhao Xiaoyu, Jin Xiaohui, Li Jiayan, Liu Yuanchen, Liu Huan, Hu Ye-Fan, Chen Zhe, Xiao Yuxin, Wang Lei, Wang Yajie, He Yixin, Chai Yue, Hu Bingjie, Shuai Huiping, Wang Yang, Li Xiangnan, Jiang Shujun, Zhang Yanliang, Zhang Xiaojuan, Chan Wan-Mui, Chen Lin-Lei, Cai Jian-Piao, Sui Baokun, Zhang Honglei, Yang Dong, Zhu Longchao, Yuan Shuofeng, Zhou Jie, Huang Jian-Dong, Yuen Kwok-Yung, To Kelvin Kai-Wang, Chan Jasper Fuk-Woo, Zhang Bao-Zhong, Wang Qiao, He Maozhou, Sun Lei, Wang Pengfei, Chu Hin

An orally available M(pro)/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.

一种口服有效的 M(pro)/TMPRSS2 双特异性抑制剂,在体内具有强大的抗冠状病毒功效

Shuai Huiping, Qiao Jingxin, Yoon Chaemin, Zhang Guo, Hou Yuxin, Xia Xiaoyan, Wang Lei, Deng Xinyue, Wang Yifei, Li Qingquan, Du Lianzhao, Liu Yuanchen, Zhou Minmin, Wong Hoi Ting, Hu Jiaheng, Liu Huan, Hu Bingjie, Wang Dong, Su Jingyi, Pan Yuying, Ye Yongtao, Chen Yan, Fang Zhen, Xia Ziyi, Chai Yue, Shi Jialu, Wang Yang, Zhu Tianrenzheng, Zhang Honglei, Yuan Shuofeng, Zhou Jie, Chan Jasper Fuk-Woo, Yuen Kwok-Yung, Xu Chunfu, Lei Jian, Yang Shengyong, Chu Hin

Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan-Sarbecoviruses.

新型三特异性中和抗体,对泛沙贝病毒具有增强的效力和广谱性

Qiao Rui, Liu Yuanchen, Mao Qiyu, Li Jiayan, Lu Yinying, Shi Jialu, Li Chen, Yu Jizhen, Gong Jiami, Wang Xun, Shao Yuchen, Sun Lei, Zhang Wenhong, Yu Hongjie, Chu Hin, Wang Pengfei, Zhao Xiaoyu

Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury

仿生纳米囊泡通过溶栓和预防缺血再灌注损伤,依次治疗不同缺血持续时间的皮瓣。

Yang, Linzhong; Liu, Yuanchen; Tao, Cheng; Cao, Zichen; Guo, Shilin; Wei, Zheng; Wang, Yanyi; Liu, Tao; Chen, Lin; Xiong, Ke; Luo, Xingyu; Ran, Jianchuan; Han, Wei

Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection.

由单一祖先 SARS-CoV-2 感染引起的针对沙贝病毒的强效且广谱中和抗体

Yu Lei, Wang Yajie, Liu Yuanchen, Xing Xiaomin, Li Chen, Wang Xun, Shi Jialu, Ma Wentai, Li Jiayan, Chen Yanjia, Qiao Rui, Zhao Xiaoyu, Tian Shilei, Gao Ming, Wen Shuhua, Xue Yingxue, Qiu Tianyi, Yu Hongjie, Guan Yongjun, Chu Hin, Sun Lei, Wang Pengfei

Synergistic effects of repeated transcranial magnetic stimulation and mesenchymal stem cells transplantation on alleviating neuroinflammation and PANoptosis in cerebral ischemia

重复经颅磁刺激与间充质干细胞移植对减轻脑缺血神经炎症和全脑凋亡的协同作用

Shimei Cheng #, Qiying Lu #, Qiuli Liu #, Yuanchen Ma, Jinshuo Chen, Di Lu, Mudan Huang, Yinong Huang, Erming Zhao, Jing Luo, Haiqing Zheng

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5

SARS-CoV-2 Omicron 主要亚系 BA.1、BA.2 和 BA.5 的病毒适应度和内在致病性

Huiping Shuai, Jasper Fuk-Woo Chan, Bingjie Hu, Yue Chai, Chaemin Yoon, Huan Liu, Yuanchen Liu, Jialu Shi, Tianrenzheng Zhu, Jing-Chu Hu, Ye-Fan Hu, Yuxin Hou, Xiner Huang, Terrence Tsz-Tai Yuen, Yang Wang, Jinjin Zhang, Yao Xia, Lin-Lei Chen, Jian-Piao Cai, Anna Jinxia Zhang, Shuofeng Yuan, Jie Zho

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2

刺突突变导致 SARS-CoV-2 omicron BA.1 和 BA.2 进入偏好发生改变

Bingjie Hu, Jasper Fuk-Woo Chan, Huan Liu, Yuanchen Liu, Yue Chai, Jialu Shi, Huiping Shuai, Yuxin Hou, Xiner Huang, Terrence Tsz-Tai Yuen, Chaemin Yoon, Tianrenzheng Zhu, Jinjin Zhang, Wenjun Li, Anna Jinxia Zhang, Jie Zhou, Shuofeng Yuan, Bao-Zhong Zhang, Kwok-Yung Yuen, Hin Chu